David F. Hale is a founder and has served as a member of Oncternal’s board since 2013 and as Chairman of the board since December 2018. Mr. Hale has served as Chairman & CEO of Hale Biopharma Ventures, LLC since May 2006. He is a serial entrepreneur who has been involved in the formation and development of numerous life sciences companies. He was previously President and CEO of CancerVax Corporation, a cancer therapeutic company from October 2000 through May 2006 when CancerVax merged with Micromet, Inc. He became Chairman of Micromet, Inc. until the sale of the company to Amgen Inc. in 2012. After joining Hybritech, Inc., in 1982, he was President & Chief Operating Officer and became CEO in 1986, when Hybritech was acquired by Eli Lilly and Co. From 1987 to 1997 he was Chairman, President and CEO of Gensia, Inc. He was a co-founder and Chairman of Viagene, Inc. from 1987 to 1995. He was President and CEO of Women First HealthCare, Inc. from January 1998 to June 2000. Prior to joining Hybritech in 1982, Mr. Hale was Vice President and General Manager of BBL Microbiology Systems, a division of Becton, Dickinson & Co. and from 1971 to 1980, held various marketing and sales management positions with Ortho Pharmaceutical Corporation, a division of Johnson & Johnson, Inc. Mr. Hale also serves as Chairman of Biocept, Inc. Mr. Hale previously served as Chairman of Santarus, Inc., Somaxon, Inc., SkinMedica, Inc., CRISIMed, Inc. and Agility Clinical, Inc. He also serves as Chairman of a number of privately held companies, including MDR Aesthetics Inc., Recros Medica, Inc., Clarify Medical, Inc., Neurana Pharmaceuticals, Inc. and Adigica Health, Inc., and as a Director of Neurelis, Inc. Mr. Hale also is a co-founder and serves on the Board of Directors of BIOCOM, is a former member of the board of Biotechnology Industry Organization, or BIO, and the Biotechnology Institute. Mr. Hale also serves as a member of the board of directors of the San Diego Economic Development Corporation, as a board trustee of Rady Children’s Hospital of San Diego, Chairman of the board of Rady Children’s Institute of Pediatric Genomics and a trustee of the Salk Institute. He is a co-founder of the CONNECT Program in Technology and Entrepreneurship. Mr. Hale holds a B.A. in Biology and Chemistry from Jacksonville State University.
What is David F. Hale's net worth?
The estimated net worth of David F. Hale is at least $828.24 as of February 23rd, 2024. Mr. Hale owns 714 shares of Oncternal Therapeutics stock worth more than $828 as of November 21st. This net worth estimate does not reflect any other assets that Mr. Hale may own. Learn More about David F. Hale's net worth.
How do I contact David F. Hale?
Has David F. Hale been buying or selling shares of Oncternal Therapeutics?
David F. Hale has not been actively trading shares of Oncternal Therapeutics over the course of the past ninety days. Most recently, on Friday, February 23rd, David F. Hale bought 714 shares of Oncternal Therapeutics stock. The stock was acquired at an average cost of $9.04 per share, with a total value of $6,454.56. Following the completion of the transaction, the director now directly owns 714 shares of the company's stock, valued at $6,454.56. Learn More on David F. Hale's trading history.
Who are Oncternal Therapeutics' active insiders?
Are insiders buying or selling shares of Oncternal Therapeutics?
In the last year, Oncternal Therapeutics insiders bought shares 3 times. They purchased a total of 10,714 shares worth more than $92,735.84. The most recent insider tranaction occured on April, 8th when Director Robert James Wills bought 3,086 shares worth more than $27,650.56. Insiders at Oncternal Therapeutics own 11.2% of the company.
Learn More about insider trades at Oncternal Therapeutics. Information on this page was last updated on 4/8/2024.
